Earnings Feed
Start Free
Home/Filings/4/0001209191-14-020603
4//SEC Filing

AQUINOX PHARMACEUTICALS, INC 4

Accession 0001209191-14-020603

$NGNECIK 0001404644operating
View on SEC.govCompany Profile

Filed

Mar 13, 8:00 PM ET

Accepted

Mar 14, 3:37 PM ET

Size

58.3 KB

Accession

0001209191-14-020603

Insider Transaction Report

Form 4
Period: 2014-03-12
AQUINOX PHARMACEUTICALS, INCAQXP
Bridger Gary
Director
Transactions
  • Conversion

    Series A-2 Preferred Stock

    2014-03-12+189,393→ 0 total(indirect: See Note)
    → Common Stock (189,393 underlying)
  • Disposition to Issuer

    Common Special Voting Stock

    2014-03-12−40,147→ 0 total(indirect: See Note)
  • Disposition to Issuer

    Series A-1 Special Voting Stock

    2014-03-12−284,090→ 0 total(indirect: See Note)
  • Disposition to Issuer

    Series B-1 Special Voting Stock

    2014-03-12−326,538→ 0 total(indirect: See Note)
  • Disposition to Issuer

    Series C Special Voting Stock

    2014-03-12−378,786→ 0 total(indirect: See Note)
  • Award

    Common Exchangeable Shares

    2014-03-12$11.00/sh+36,502$401,522→ 40,147 total(indirect: See Note)
    → Common Stock (36,502 underlying)
  • Conversion

    Series A-1 Exchangeable Shares

    2014-03-12−284,090→ 0 total(indirect: See Note)
    → Series A-1 Preferred Stock (284,090 underlying)
  • Disposition to Issuer

    Series A-2 Special Voting Stock

    2014-03-12−189,393→ 0 total(indirect: See Note)
  • Conversion

    Series A-1 Preferred Stock

    2014-03-12−284,090→ 0 total(indirect: See Note)
    → Common Stock (284,090 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2014-03-12+325,035→ 0 total(indirect: See Note)
    → Common Stock (325,035 underlying)
  • Conversion

    Series C Exchangeable Shares

    2014-03-12−378,786→ 0 total(indirect: See Note)
    → Series C Preferred Stock (378,786 underlying)
  • Conversion

    Series B-2 Exchangeable Shares

    2014-03-12−325,035→ 0 total(indirect: See Note)
    → Series B-2 Preferred Stock (325,035 underlying)
  • Conversion

    Series C Preferred Stock

    2014-03-12+378,786→ 0 total(indirect: See Note)
    → Common Stock (378,786 underlying)
  • Award

    Common Special Voting Stock

    2014-03-12+36,502→ 40,147 total(indirect: See Note)
  • Disposition to Issuer

    Series B-2 Special Voting Stock

    2014-03-12−325,035→ 0 total(indirect: See Note)
  • Conversion

    Common Stock

    2014-03-12+1,543,989→ 1,543,989 total(indirect: See Note)
  • Conversion

    Common Exchangeable Shares

    2014-03-12−40,147→ 0 total(indirect: See Note)
    → Common Stock (40,147 underlying)
  • Conversion

    Series A-1 Preferred Stock

    2014-03-12+284,090→ 0 total(indirect: See Note)
    → Common Stock (284,090 underlying)
  • Conversion

    Series A-2 Exchangeable Shares

    2014-03-12−189,393→ 0 total(indirect: See Note)
    → Series A-2 Preferred Stock (189,393 underlying)
  • Conversion

    Series B-1 Exchangeable Shares

    2014-03-12−326,538→ 0 total(indirect: See Note)
    → Series B-1 Preferred Stock (326,538 underlying)
  • Conversion

    Series C Preferred Stock

    2014-03-12−378,786→ 0 total(indirect: See Note)
    → Common Stock (378,786 underlying)
  • Conversion

    Series A-2 Preferred Stock

    2014-03-12−189,393→ 0 total(indirect: See Note)
    → Common Stock (189,393 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2014-03-12+326,538→ 0 total(indirect: See Note)
    → Common Stock (326,538 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2014-03-12−326,538→ 0 total(indirect: See Note)
    → Common Stock (326,538 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2014-03-12−325,035→ 0 total(indirect: See Note)
    → Common Stock (325,035 underlying)
Footnotes (5)
  • [F1]Dr. Bridger is a managing director of Five Corners Capital Inc., the general partner of Ventures West 8 Limited Partnership. Dr. Bridger may be deemed to have voting and investment power with respectto shares held by Ventures West 8 Limited Partnership. Dr. Bridger disclaimes benefical ownership of such shares except to the extent of any pecuniary interest.
  • [F2]Each share of the issuer's Common, Series A-1, Series A-2, Series B-1, Series B-2 and Series C Special Voting Stock was redeemed upon the closing of the issuer's initial public offering for $0.0000192 per share.
  • [F3]Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date.
  • [F4]The Common Exchangeable Shares of Aquinox Pharmaceuticals Inc., a corporation under the Canadian Business Corporations Act ("AQXP Canada"), were exchanged for Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and have no expiration date.
  • [F5]The Series A-1, Series A-2, Series B-1, Series B-2 and Series C Exchangeable Shares of AQXP Canada were exchanged for Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock, respectively, of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and have no expiration date.

Documents

1 file

Issuer

AQUINOX PHARMACEUTICALS, INC

CIK 0001404644

→
Entity typeoperating

Related Parties

1
  • filerCIK 0001404644

Filing Metadata

Form type
4
Filed
Mar 13, 8:00 PM ET
Accepted
Mar 14, 3:37 PM ET
Size
58.3 KB
View on SEC.gov